|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,515 GBX | +0.75% |
|
-0.76% | +4.43% |
| 01:06pm | GSK : UBS keeps its Buy rating | ZD |
| 07-03 | Health Stocks Slip in Risk-On Trade -- Health Care Roundup | DJ |
Jan 21 (Reuters) - Viiv Healthcare:
* VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF CABENUVA (CABOTEGRAVIR, RILPIVIRINE), THE FIRST AND ONLY COMPLETE LONG-ACTING REGIMEN FOR HIV TREATMENT
* VIIV HEALTHCARE SAYS WILL BEGIN SHIPPING CABENUVA TO WHOLESALERS AND SPECIALTY DISTRIBUTORS IN THE US IN FEBRUARY 2021
| 1st Jan change | Capi. | |
|---|---|---|
| +4.43% | 78.26B | |
| +54.07% | 809B | |
| +39.52% | 621B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +14.75% | 238B | |
| -0.41% | 221B | |
| +14.48% | 218B | |
| +7.42% | 166B |
GSK PLC 
